The pseudonym "Philo Vaihinger" has been abandoned. All posts have been and are written by me, Joseph Auclair.

Tuesday, February 14, 2017

Is this how drug companies should recoup research and development costs?

EpiPen alternative to hit market at more than seven times the price

Pharmaceutical company Kaléo – already under fire for raising the price of an overdose antidote – now plans to put an alternative to the EpiPen on the market for more than seven times the cost of the leading $608 drug.

Kaléo’s epinephrine injector, used to stop severe allergic reactions, will go on sale for $4,500 for a pack of two beginning on 14 February. 

The auto-injector’s innovative audio instructions walk caregivers through administering less than $5 worth of epinephrine.

There has got to be a better way, consistent with private enterprise leading the march in this area, taking risks and reaping rewards.

No comments:

Post a Comment